MorphoSys Presents New Long-Term Data from L-MIND Suggesting Durable Response to Treatment with Monjuvi (tafasitamab-cxix) for Patients with R/R DLBCL

BOSTON - MorphoSys USA, Inc., a fully owned subsidiary of MorphoSys AG , announced data from the ongoing L-MIND study showing that Monjuvi plus lenalidomide followed by Monjuvi monotherapy provided... | September 29, 2022

Related Keywords

Germany ,United States ,United Kingdom ,Texas ,Planegg ,Bayern ,Massachusetts ,Boston ,Houston ,Canada ,Kaitlyn Nealy ,Thomas Biegi ,Johannes Duell ,Julia Neugebauer ,Development Officer ,Linkedin ,Xencor Inc ,Twitter ,Drug Administration ,Nasdaq ,Us Communications ,Exchange Commission ,University Hospital Wuerzburg Medical Clinic ,Morphosys United States Inc ,Society Of Hematologic Oncology ,Sys United States ,Tenth Annual Meeting ,Hematologic Oncology ,Sys Chief Research ,Hospital Wuerzburg Medical Clinic ,Antibody Dependent Cell Mediated Cytotoxicity ,Antibody Dependent Cellular Phagocytosis ,Medication Guide ,Prescribing Information ,Patient Information ,Important Safety ,News Publishing ,Xencor ,Nc Stock Exchange ,News ,Information ,Press Release ,Morphosys ,Bully ,Wned ,Ubsidiary ,F ,G ,Nnounced ,Data ,Rom ,The ,Ngoing ,Study ,Showing ,Hat ,Monjuvi ,Plus ,Lenalidomide ,Ollowed ,Y ,Onotherapy Xncr Us98401f1057 ,